181 related articles for article (PubMed ID: 34944112)
21. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
24. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834
[TBL] [Abstract][Full Text] [Related]
25. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Kato Y; Ohishi T; Kawada M; Maekawa N; Konnai S; Itai S; Yamada S; Kaneko MK
Biochem Biophys Rep; 2019 Mar; 17():23-26. PubMed ID: 30519645
[TBL] [Abstract][Full Text] [Related]
26. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Derer S; Berger S; Schlaeth M; Schneider-Merck T; Klausz K; Lohse S; Overdijk MB; Dechant M; Kellner C; Nagelmeier I; Scheel AH; Lammerts van Bueren JJ; van de Winkel JG; Parren PW; Peipp M; Valerius T
Neoplasia; 2012 Mar; 14(3):190-205. PubMed ID: 22496619
[TBL] [Abstract][Full Text] [Related]
28. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
29. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract][Full Text] [Related]
30. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
32. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG
Kawabata H; Ohishi T; Suzuki H; Asano T; Kawada M; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2022 Dec; 41(6):320-327. PubMed ID: 35483055
[TBL] [Abstract][Full Text] [Related]
33. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
[TBL] [Abstract][Full Text] [Related]
34. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
[TBL] [Abstract][Full Text] [Related]
35. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
[TBL] [Abstract][Full Text] [Related]
36. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
[TBL] [Abstract][Full Text] [Related]
37. Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas.
Kaneko MK; Ohishi T; Takei J; Sano M; Nakamura T; Hosono H; Yanaka M; Asano T; Sayama Y; Harada H; Kawada M; Kato Y
Oncol Rep; 2020 Dec; 44(6):2517-2526. PubMed ID: 33125138
[TBL] [Abstract][Full Text] [Related]
38. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
[TBL] [Abstract][Full Text] [Related]
39. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
[TBL] [Abstract][Full Text] [Related]
40. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
